Exploring JAK Inhibitors in Polymyalgia Rheumatica Treatment

This chapter explores the impact of JAK inhibitors, particularly cerulamab and baricitinib, in treating polymyalgia rheumatica (PMR). It highlights recent research on their efficacy, potential shifts in treatment protocols, and the improving accessibility of these therapies as patent protections lapse.